Combination gene delivery of the cell cycle inhibitor p27 with thymidine kinase enhances prodrug cytotoxicity

Journal of Virology

Volumn 72, Issue 11, 1998, Pages 9201-9207

  Danthinne, Xavier ^b,c   Aoki, Kazunori ^a,b   Kurachi, Akiko L ^b   Nabel, Gary J ^a,b   Nabel, Elizabeth G ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Boise VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CYCLIN DEPENDENT KINASE INHIBITOR; GANCICLOVIR; HYBRID PROTEIN; PRODRUG; PROTEIN P16; PROTEIN P21; PROTEIN P27; THYMIDINE KINASE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL KILLING; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG CYTOTOXICITY; GENE MUTATION; GENE TARGETING; GENE TRANSFER; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS 1; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; VIRUS GENE;

EID: 0031680640     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.11.9201-9207.1998     Document Type: Article

References (42)

1. Benedetti, S., F. Dimeco, B. Pollo, N. Cirenei, B. M. Colombo, M. G. Bruzzone, E. Cattaneo, A. Vescovi, S. Didonato, M. P. Colombo, and G. Finocchiaro. 1997. Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. Hum. Gene Ther. 8:1345-1353.
2. Bi, W. L., L. M. Parysek, R. Warnick, and P. J. Stambrook. 1993. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gene Ther. 4:725-731.
3. Boehme, R. E. 1984. Phosphorylation of the antiviral precursor 9-(1,3-dihydroxy-2-propoxymethyl)guanine monophosphate by guanylate kinase isoenzymes. J. Biol. Chem. 259:12346-12349.
4. Borrelli, E., R. Heyman, M. Hsi, and R. M. Evans. 1988. Targeting of an inducible toxic phenotype in animal cells. Proc. Natl. Acad. Sci. USA 85: 7572-7576.
5. Breakefield, X. O., and N. A. DeLuca. 1991. Herpes simplex virus for gene delivery to neurons. New Biol. 3:203-218.
6. Chen, S. H., K. Kosai, B. Xu, K. Pham-Nguyen, C. Contant, M. J. Finegold, and S. L. Woo. 1996. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res. 56:3758-3762.
7. Colombo, B. M., S. Benedetti, S. Ottolenghi, M. Mora, B. Pollo, G. Poli, and G. Finocchiaro. 1995. The "bystander effect": association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum. Gene Ther. 6:763-772.
8. Culver, K. W., Z. Ram, S. Wallbridge, H. Ishii, E. H. Oldfield, and R. M. Blaese. 1992. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256:1550-1552.
9. Di Marzio, P., S. Choe, M. Ebright, R. Knoblauch, and N. R. Landau. 1995. Mutational analysis of cell cycle arrest, nuclear localization, and virion packaging of human immunodeficiency virus type 1 Vpr. J. Virol. 69:7909-7916.
10. Ezzeddine, Z. D., R. L. Martuza, D. Platika, M. P. Short, A. Malick, B. Choi, and X. O. Breakefield. 1991. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. 3:608-614.
11. Fick, J., F. G. Barker, P. Dazin, E. M. Westphale, E. C. Beyer, and M. A. Israel. 1995. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc. Natl. Acad. Sci. USA 92:1071-11075.
12. Freeman, S. M., C. N. Abboud, K. A. Whartenby, C. H. Packman, D. S. Koeplin, F. L. Moolten, and G. N. Abraham. 1993. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53:5274-5283.
13. Freeman, S. M., K. A. Whartenby, J. L. Freeman, C. N. Abboud, and A. J. Marrogi. 1996. In situ use of suicide genes for cancer therapy. Semin. Oncol. 23:31-45.
14. Gordon, J. W., G. A. Scangos, D. J. Plotkin, J. A. Barbosa, and F. H. Ruddle. 1980. Genetic transformation of mouse embryos by microinjection of purified DNA. Proc. Natl. Acad. Sci. USA 77:7380-7384.
15. Graham, F. L., J. Smiley, W. C. Russel, and R. Nairn. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59-74.
16. Haar, H., and T. Flatmark. 1987. Evidence that deletion of coding sequences in the 5′ end of the thymidine kinase gene of herpes simplex virus type 1 affects the stability of the gene products. J. Gen. Virol. 68:2817-2829.
17. Heyman, R. A., E. Borrelli, J. Lesley, D. Anderson, D. D. Richman, S. M. Baird, R. Hyman, and R. M. Evans. 1989. Thymidine kinase obliteration: creation of transgenic mice with controlled immune deficiency. Proc. Natl. Acad. Sci. USA 86:2698-2702.
18. Luca, F. C., E. K. Shibuya, C. E. Dohrmann, and J. V. Ruderman. 1991. Both cyclin AΔ60 and BΔ97 are stable and arrest cells in M-phase, but only cyclin BΔ97 turns on cyclin destruction. EMBO J. 10:4311-4320.
19. Cip1. Nature 375:159-161.
20. Kip1 by the viral E1A oncoprotein in TGFβ-treated cells. Nature 380:262-265.
21. Moolten, F. L., J. M. Wells, R. A. Heyman, and R. M. Evans. 1990. Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum. Gene Ther. 1:125-134.
22. Moolten, F. L., and J. M. Wells. 1990. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 82:297-300.
23. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63.
24. Muller, D. W. M., D. Gordon, H. San, Z.-Y. Yang, V. J. Pompili, G. J. Nabel, and E. G. Nabel. 1994. Catheter-mediated pulmonary vascular gene transfer and expression. Circ. Res. 75:1039-1049.
25. Ohno, T., Z.-Y. Yang, L. Xu, M. Jaffe, E. G. Nabel, D. Normolle, and G. J. Nabel. 1997. Combination gene transfer to potentiate tumor regression. Gene Ther. 4:361-366.
26. O'Malley, B. W., K. A. Cope, S. H. Chen, D. Li, M. R. Schwartz, and S. L. Woo. 1996. Combination gene therapy for oral cancer in a murine model. Cancer Res. 56:1737-1741.
27. O'Malley, B. W., Jr., D. A. Sewell, D. Li, K. Kosai, S. H. Chen, S. L. Woo, and L. Duan. 1997. The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer. Mol. Endocrinol. 11:667-673.
28. Pagano, M., S. W. Tam, A. M. Theodoras, P. Beer-Romero, G. Del Sal, V. Chau, P. R. Yew, G. F. Draetta, and M. Rolfe. 1995. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685.
29. Plautz, G., E. G. Nabel, and G. J. Nabel. 1991. Selective elimination of recombinant genes in vivo with a suicide retroviral vector. New Biol. 3:709-715.
30. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66.
31. Ram, Z., S. Walbridge, J. D. Heiss, K. W. Culver, R. M. Blaese, and E. H. Oldfield. 1994. In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors. J. Neurosurg. 80:535-540.
32. Reynisdottir, I., K. Polyak, A. Iavarone, and J. Massague. 1995. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev. 9:1831-1845.
33. Rogulski, K. R., J. H. Kim, S. H. Kim, and S. O. Freytag. 1997. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum. Gene Ther. 8:73-85.
34. Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-CDK2 complex. Nature 382:325-331.
35. Samejima, Y., and D. Meruelo. 1995. 'Bystander killing' induces apoptosis and is inhibited by forskolin. Gene Ther. 2:50-58.
36. Schmid, I., C. H. Uitteenbogaart, and J. V. Giorgi. 1991. A gentle fixation and permeabilization method for combined cell surface and intracellular staining with improved precision in DNA quantification. Cytometry 12:279-285.
37. Serrano, M., G. J. Hannon, and D. Beach. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707.
38. Sheaff, R. J., M. Groudine, M. Gordon, J. Roberts, and B. E. Clurman. 1997. Cyclin E-CDK2 is a regulator of p27-Kip1. Genes Dev. 11:1464-1478.
39. St. Clair, M. H., C. V. Lambe, and P. A. Furman. 1987. Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Antimicrob. Agents Chemother. 31:844-849.
40. Tanner, F. C., Z.-Y. Yang, D. Gordon, G. J. Nabel, and E. G. Nabel. 1998. Expression of cyclin-dependent kinase inhibitors in cardiovascular disease. Circ. Res. 82:396-403.
41. Toyoshima, H., and T. Hunter. 1994. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78:67-74.
42. Yang, Z.-Y., N. D. Perkins, T. Ohno, E. G. Nabel, and G. J. Nabel. 1995. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat. Med. 1:1052-1056.